Collegium Pharmaceutical’s acquisition of BioDelivery Sciences International brings a pain drug that’s administered in a different way than its current lineup of medicines. The deal also gives Collegium a way to break into the neurology market.
Collegium Pharmaceutical’s acquisition of BioDelivery Sciences International brings a pain drug that’s administered in a different way than its current lineup of medicines. The deal also gives Collegium a way to break into the neurology market.
Copyright © 2024 | WordPress Theme by MH Themes